[go: up one dir, main page]

EE200300139A - Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks - Google Patents

Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks

Info

Publication number
EE200300139A
EE200300139A EEP200300139A EEP200300139A EE200300139A EE 200300139 A EE200300139 A EE 200300139A EE P200300139 A EEP200300139 A EE P200300139A EE P200300139 A EEP200300139 A EE P200300139A EE 200300139 A EE200300139 A EE 200300139A
Authority
EE
Estonia
Prior art keywords
preparation
treatment
pharmaceutical composition
multiple sclerosis
loss diseases
Prior art date
Application number
EEP200300139A
Other languages
English (en)
Inventor
Proudfoot Amanda
N. C. Wells Timothy
Kosco-Vilbois Marie
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200300139A publication Critical patent/EE200300139A/et
Publication of EE05174B1 publication Critical patent/EE05174B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300139A 2000-10-04 2001-10-03 Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks EE05174B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EE200300139A true EE200300139A (et) 2003-06-16
EE05174B1 EE05174B1 (et) 2009-06-15

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300139A EE05174B1 (et) 2000-10-04 2001-10-03 Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks

Country Status (30)

Country Link
US (1) US7402303B2 (et)
EP (1) EP1326628B1 (et)
JP (1) JP3908165B2 (et)
KR (1) KR100837898B1 (et)
CN (1) CN1285381C (et)
AR (1) AR030854A1 (et)
AT (1) ATE265222T1 (et)
AU (2) AU2002215919B2 (et)
BG (1) BG66137B1 (et)
BR (1) BR0114407A (et)
CA (1) CA2423616C (et)
CZ (1) CZ303409B6 (et)
DE (1) DE60103078T2 (et)
DK (1) DK1326628T3 (et)
EA (1) EA006137B1 (et)
EE (1) EE05174B1 (et)
ES (1) ES2217199T3 (et)
HR (1) HRP20030215B1 (et)
HU (1) HUP0302194A3 (et)
IL (2) IL155178A0 (et)
MX (1) MXPA03003008A (et)
NO (1) NO330278B1 (et)
PL (1) PL204231B1 (et)
PT (1) PT1326628E (et)
RS (1) RS50738B (et)
SI (1) SI1326628T1 (et)
SK (1) SK287523B6 (et)
UA (1) UA77950C2 (et)
WO (1) WO2002028419A2 (et)
ZA (1) ZA200302315B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051921A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
US7335350B2 (en) 2002-04-04 2008-02-26 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
AU2003302755B2 (en) * 2002-12-23 2009-01-08 Laboratoires Serono Sa Use of CC-chemokine mutants against liver diseases
WO2005040210A2 (en) * 2003-10-22 2005-05-06 Applied Research Systems Ars Holding N.V. Novel cxcl8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
ATE322506T1 (de) * 2004-01-19 2006-04-15 Ares Trading Sa Verfahren zur reinigung von in bakterien exprimierten proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP2218748B1 (en) * 2005-09-03 2012-10-10 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
WO2011097640A1 (en) * 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
CA2316447C (en) 1997-12-23 2009-07-28 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
EP1148889A2 (en) 1999-01-29 2001-10-31 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
ATE265222T1 (de) 2004-05-15
DE60103078D1 (de) 2004-06-03
CZ303409B6 (cs) 2012-09-05
EA006137B1 (ru) 2005-10-27
CA2423616C (en) 2010-03-16
SK287523B6 (sk) 2011-01-04
HK1062811A1 (en) 2004-11-26
HUP0302194A3 (en) 2005-12-28
AU1591902A (en) 2002-04-15
HRP20030215B1 (en) 2011-09-30
RS50738B (sr) 2010-08-31
MXPA03003008A (es) 2003-07-14
PL204231B1 (pl) 2009-12-31
HRP20030215A2 (en) 2005-02-28
IL155178A0 (en) 2003-11-23
SK4062003A3 (en) 2003-08-05
PT1326628E (pt) 2004-09-30
JP3908165B2 (ja) 2007-04-25
NO20031525D0 (no) 2003-04-03
BR0114407A (pt) 2003-07-29
CZ2003947A3 (cs) 2003-11-12
DE60103078T2 (de) 2005-04-07
NO330278B1 (no) 2011-03-21
AU2002215919B2 (en) 2005-11-24
AR030854A1 (es) 2003-09-03
WO2002028419A3 (en) 2002-06-13
HUP0302194A2 (hu) 2003-10-28
BG107685A (bg) 2003-11-28
JP2004510426A (ja) 2004-04-08
IL155178A (en) 2009-07-20
US20040101509A1 (en) 2004-05-27
PL362350A1 (en) 2004-10-18
UA77950C2 (en) 2007-02-15
ES2217199T3 (es) 2004-11-01
EE05174B1 (et) 2009-06-15
NO20031525L (no) 2003-04-03
EP1326628A2 (en) 2003-07-16
CA2423616A1 (en) 2002-04-11
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
US7402303B2 (en) 2008-07-22
ZA200302315B (en) 2004-03-25
CN1477969A (zh) 2004-02-25
DK1326628T3 (da) 2004-08-09
WO2002028419A2 (en) 2002-04-11
CN1285381C (zh) 2006-11-22
EA200300439A1 (ru) 2003-08-28
SI1326628T1 (en) 2004-10-31
YU25703A (sh) 2006-05-25
EP1326628B1 (en) 2004-04-28
BG66137B1 (bg) 2011-07-29

Similar Documents

Publication Publication Date Title
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EE05180B1 (et) Asaindooli sisaldav farmatseutiline kompositsioon raviotstarbeliseks kasutamiseks, asaindoolid ning nende kasutamine ravimite valmistamiseks, mis on ette n„htud proteiinikinaasi kataltilise toime p„rssimiseks
NO20003218L (no) Oral farmasøytisk doseringsform med forlenget frigivningsvirkning
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
HRP20030046A2 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200300139A (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud hulgiskleroosi ja teiste müeliinikaotusega seotud haiguste raviks
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
EE200200620A (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nähtud ateroskleroosi ravimiseks ja/või ennetamiseks
EE200300363A (et) N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
NO20002526D0 (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
HUP0103686A2 (en) Use of rolipram, ariflo or diazepino-indole, triazolo-quinazoline derivatives for the preparation of pharmaceutical compositions preventing or treating diseases associated with an excess in il-12 production
HUP0300876A3 (en) Use of diclofenac for the manufacture of medicament for the topical treatment of burns

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20131003